MicroPort CardioFlow Medtech Corp. (HK:2160) has released an update.
MicroPort CardioFlow Medtech Corporation has entered into two key agreements with Kewei Medical, securing an exclusive distribution right for their products in China until the end of 2025 and providing a RMB 10 million loan to Kewei Medical. These transactions are significant enough to require reporting and annual review but fall below the threshold for needing shareholder approval. The agreements strengthen MP CardioFlow’s market position and financial relationship with Kewei Medical, a subsidiary of its majority shareholder, MicroPort.
For further insights into HK:2160 stock, check out TipRanks’ Stock Analysis page.
